

# NYSTATIN AND TRIAMCINOLONE ACETONIDE - nystatin and triamcinolone acetonide ointment

Actavis Pharma, Inc.

Reference Label Set Id: 89dd2be9-164a-42fe-9e9e-cc507e8fc928

## Nystatin and Triamcinolone Acetonide Ointment, USP


Rx Only

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.


### DESCRIPTION

Nystatin and Triamcinolone Acetonide Ointment, USP for dermatologic use contains the antifungal agent nystatin and the synthetic corticosteroid triamcinolone acetonide.

Nystatin is a polyene antimycotic obtained from *Streptomyces noursei*. It is a yellow to light tan powder with a cereal-like odor, very slightly soluble in water, and slightly to sparingly soluble in alcohol. It has a structural formula of  $C_{47}H_{75}NO_{17}$  and a molecular weight of 926.13.



Triamcinolone acetonide is designated chemically as 9-fluoro-11 $\beta$ , 16 $\alpha$ , 17, 21-tetrahydroxy-pregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone. The white to cream crystalline powder has a slight odor, is practically insoluble in water, and very soluble in alcohol. It has a structural formula of  $C_{24}H_{31}FO_6$  and a molecular weight of 434.50.



Each gram of Nystatin and Triamcinolone Acetonide Ointment, USP provides 100,000 Nystatin units and 1 mg Triamcinolone Acetonide in an ointment base of mineral oil and white petrolatum.

## CLINICAL PHARMACOLOGY

### Nystatin

Nystatin exerts its antifungal activity against a variety of pathogenic and nonpathogenic yeasts and fungi by binding to sterols in the cell membrane. The binding process renders the cell membrane incapable of functioning as a selective barrier. Nystatin provides specific anticandidal activity to *Candida* (Monilia) *albicans* and other *Candida* species, but it is not active against bacteria, protozoa, trichomonads, or viruses. Nystatin is not absorbed from intact skin or mucous membranes.

### Triamcinolone Acetonide

Triamcinolone acetonide is primarily effective because of its anti-inflammatory, anti-pruritic and vasoconstrictive actions, characteristic of the topical corticosteroid class of drugs. The pharmacological effects of the topical corticosteroids are well known; however, the mechanisms of their dermatologic actions are unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

### Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings (see **DOSAGE AND ADMINISTRATION**).

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see **DOSAGE AND ADMINISTRATION**).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

### Nystatin and Triamcinolone Acetonide

During clinical studies of mild to severe manifestations of cutaneous candidiasis, patients treated with nystatin and triamcinolone acetonide showed a faster and more pronounced clearing of erythema and pruritis than patients treated with nystatin or triamcinolone acetonide alone.

## INDICATIONS AND USAGE

Nystatin and Triamcinolone Acetonide Ointment, USP is indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.

## CONTRAINDICATIONS

This preparation is contraindicated in those patients with a history of hypersensitivity to any of its components.

## PRECAUTIONS

### General

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some

patients. Conditions that augment systemic absorption include application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings (see **DOSAGE AND ADMINISTRATION**).

Therefore, patients receiving a large dose of any potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of internal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, or substitute a less potent steroid.

Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see **PRECAUTIONS, Pediatric Use**).

If irritation or hypersensitivity develops with the combination nystatin and triamcinolone acetonide, treatment should be discontinued and appropriate therapy instituted.

### **Information for the Patient**

Patients using this medicine should receive the following information and instructions.

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occluded (see **DOSAGE AND ADMINISTRATION**).
4. Patients should report any signs of local adverse reactions.
5. When using this medication in the inguinal area, patients should be advised to apply ointment sparingly and to wear loose fitting clothing.
6. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
7. Patients should be advised on preventative measures to avoid reinfection.

### **Laboratory Tests**

If there is a lack of therapeutic response, appropriate microbiological studies (e.g., KOH smears and/or cultures) should be repeated to confirm the diagnosis and rule out other pathogens, before instituting another course of therapy.

A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating hypothalamic-pituitary-adrenal (HPA) axis suppression due to corticosteroids.

### **Carcinogenesis, Mutagenesis, and Impairment of Fertility**

Long-term animal studies have not been performed to evaluate the carcinogenic or mutagenic potential or possible impairment of fertility in males or females.

### **Pregnancy: Teratogenic Effects—Pregnancy Category C**

There are no teratogenic studies with combined nystatin and triamcinolone acetonide. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Therefore, any topical corticosteroid preparation should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Topical preparations containing corticosteroids should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

### **Nursing Mothers**

It is not known whether any component of this preparation is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised during use of this preparation by a nursing woman.

### **Pediatric Use**

In clinical studies of a limited number of pediatric patients ranging in age from two months through 12 years, nystatin and triamcinolone acetonide cream formulation cleared or significantly ameliorated the disease state in most patients.

**Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.**

HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

### **ADVERSE REACTIONS**

A single case (approximately one percent of patients studied) of acneiform eruption occurred with use of combined nystatin and triamcinolone acetonide in clinical studies.

Nystatin is virtually nontoxic and nonsensitizing and is well tolerated by all age groups, even during prolonged use. Rarely, irritation may occur.

The following local adverse reactions are reported infrequently with topical corticosteroids (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, perioral secondary infection, skin atrophy, striae and miliaria.

**To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

### **OVERDOSAGE**

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see **PRECAUTIONS, General**); however, acute overdosage and serious adverse effects with dermatologic use are unlikely.

### **DOSAGE AND ADMINISTRATION**

A thin film of Nystatin and Triamcinolone Acetonide Ointment is usually applied to the affected areas

twice daily in the morning and evening. The preparation should be discontinued if symptoms persist after 25 days of therapy (see **PRECAUTIONS, Laboratory Tests**).

Nystatin and Triamcinolone Acetonide Ointment should *not* be used with occlusive dressings.

## **HOW SUPPLIED**

Nystatin and Triamcinolone Acetonide Ointment, USP is supplied in 15 g, 30 g, and 60 g tubes.

## **STORAGE**

**Store at 20-25°C (68-77°F)** [See USP Controlled Room Temperature]. Avoid freezing.

### **Manufactured by:**

Cosette Pharmaceuticals, Inc.  
111 Coolidge Street  
South Plainfield, NJ 07080

### **Distributed by:**

Actavis Pharma, Inc.  
Parsippany, NJ 07054 USA

Rev. 09/2019  
8-0667ACT4

## **PRINCIPAL DISPLAY PANEL**

**NDC 0472-0155-15**

**Nystatin and Triamcinolone Acetonide Ointment, USP**

**15 g**

**Rx Only**

**For Dermatologic Use Only - Not for Ophthalmic Use**

**Cosette Pharmaceuticals, Inc.**

**W**  
Actavis

NDC 0472-0155-15

# Nystatin and Triamcinolone Acetonide

## Ointment, USP

Rx Only

For Dermatologic Use Only  
Not for Ophthalmic Use

15 g (0.53 oz)

**Each Gram Contains:** 100,000 USP nystatin units and 1 mg of triamcinolone acetonide in a mineral oil-white petrolatum ointment base.

**Usual Dosage:** Apply to affected area twice daily. For complete information see accompanying insert.

**Keep out of the reach of children.**

**Store** at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

**Important:** Do not use if seal has been punctured or is not visible.

**To Open:** Use cap to puncture seal.

For lot number and expiration date see crimp of tube.

Manufactured by: Cosette Pharmaceuticals, Inc. 111 Coolidge Street, South Plainfield, NJ 07080

Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA

11-66715ACT7 Rev. 04/2020





**NDC 0472-0155-30**

**Nystatin and Triamcinolone Acetonide Ointment, USP**

**30 g**

**Rx Only**

**For Dermatologic Use Only - Not for Ophthalmic Use**

**Cosette Pharmaceuticals, Inc.**



NDC 0472-0155-30

# Nystatin and Triamcinolone Acetonide Ointment, USP

Rx Only

For Dermatologic Use Only  
Not for Ophthalmic Use

30 g (1.1 oz)

**Each Gram Contains:** 100,000 USP nystatin units and 1 mg of triamcinolone acetonide in a mineral oil-white petrolatum ointment base.

**Usual Dosage:** Apply to affected area twice daily. For complete information see accompanying insert.

**Keep out of the reach of children.**

**Store** at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

**Important:** Do not use if seal has been punctured or is not visible.

**To Open:** Use cap to puncture seal.

For lot number and expiration date see crimp of tube.

**Manufactured by:** Cosette Pharmaceuticals, Inc.  
111 Coolidge Street, South Plainfield, NJ 07080

**Distributed by:** Actavis Pharma, Inc.  
Parsippany, NJ 07054 USA

Rev. 08/2019 11-66731ACT6



Glue Flap

**Each Gram contains:** 100,000 USP nystatin units and 1 mg of triamcinolone acetonide in a mineral oil-white petrolatum ointment base.

**Usual Dosage:** Apply to affected area twice daily. For complete information see accompanying insert.

**Keep out of the reach of children.**

**Store** at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

**Important:** The opening of this product is covered by a metal tamper-evident seal. If this seal has been punctured or is not visible, do not use and return product to place of purchase.

**To Open:** To puncture the seal, reverse the cap and place the puncture top onto the tube. Push down firmly until the seal is open. To close, screw the cap back onto the tube. See carton or crimp of tube for lot number and expiration date.

**Manufactured by:**  
Cosette Pharmaceuticals, Inc.  
111 Coolidge Street  
South Plainfield, NJ 07080

**Distributed by:**  
Actavis Pharma, Inc.  
Parsippany, NJ 07054 USA

10-66731ACT4 Rev. 08/2019

GTIN 00304720155300



Clear Code Area



NDC 0472-0155-30

## Nystatin and Triamcinolone Acetonide Ointment, USP

Rx Only

For Dermatologic Use Only - Not for Ophthalmic Use

30 g (1.1 oz)



NDC 0472-0155-30

## Nystatin and Triamcinolone Acetonide Ointment, USP

Rx Only

For Dermatologic Use Only - Not for Ophthalmic Use

30 g (1.1 oz)



NDC 0472-0155-30

## Nystatin and Triamcinolone Acetonide Ointment, USP

Rx Only

For Dermatologic Use Only - Not for Ophthalmic Use

30 g (1.1 oz)

Clear Code Area



NDC 0472-0155-60

Nystatin and Triamcinolone Acetonide Ointment, USP

60 g

Rx Only

For Dermatologic Use Only - Not for Ophthalmic Use

Cosette Pharmaceuticals, Inc.

 Actavis NDC 0472-0155-60

## Nystatin and Triamcinolone Acetonide Ointment, USP

Rx Only

For Dermatologic Use Only  
Not for Ophthalmic Use

60 g (2.2 oz)

**Each Gram Contains:** 100,000 USP nystatin units and 1 mg of triamcinolone acetonide in a mineral oil-white petrolatum ointment base.

**Usual Dosage:** Apply to affected area twice daily. For complete information see accompanying insert.

**Keep out of the reach of children.**

**Store** at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

**Important:** Do not use if seal has been punctured or is not visible.

**To Open:** Use cap to puncture seal.

For lot number and expiration date see crimp of tube.

Manufactured by: Cosette Pharmaceuticals, Inc. 111 Coolidge Street, South Plainfield, NJ 07080

Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA

11-66760ACT6 Rev. 08/2019





## NYSTATIN AND TRIAMCINOLONE ACETONIDE

nystatin and triamcinolone acetonide ointment

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:0472-0155
<b>Route of Administration</b>	TOPICAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
NYSTATIN (UNII: BDF1O1C72E) (NYSTATIN - UNII:BDF1O1C72E)	NYSTATIN	100000 [USP'U] in 1 g
TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII:F446C597KA)	TRIAMCINOLONE ACETONIDE	1 mg in 1 g

### Inactive Ingredients

Ingredient Name	Strength
MINERAL OIL (UNII: T5L8T28FGP)	
PETROLATUM (UNII: 4T6H12BN9U)	

### Product Characteristics

<b>Color</b>	YELLOW (light tan)	<b>Score</b>	
<b>Shape</b>		<b>Size</b>	
<b>Flavor</b>		<b>Imprint Code</b>	
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0472-0155-15	1 in 1 CARTON	06/05/2015	
1		15 g in 1 TUBE; Type 0: Not a Combination Product		
2	NDC:0472-0155-30	1 in 1 CARTON	06/05/2015	
2		30 g in 1 TUBE; Type 0: Not a Combination Product		
3	NDC:0472-0155-60	1 in 1 CARTON	06/05/2015	
3		60 g in 1 TUBE; Type 0: Not a Combination Product		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062733	06/05/2015	

**Labeler** - Actavis Pharma, Inc. (119723554)

**Registrant** - Cosette Pharmaceuticals, Inc. (116918230)

### Establishment

Name	Address	ID/FEI	Business Operations
Cosette Pharmaceuticals, Inc.		116918230	analysis(0472-0155) , label(0472-0155) , manufacture(0472-0155) , pack(0472-0155)

Revised: 11/2020

Actavis Pharma, Inc.